市場概況

The Vitreoretinal Surgery Devices Market is anticipated to witness substantial growth, with a projected increase from USD 1.49 億で 2022 米ドルへ 1.85 10億まで 2029. This growth is expected to be driven by a compound annual growth rate (CAGR) の 3.0% の予測期間中に 2023-2029. Vitreoretinal surgery devices play a crucial role in the treatment of various eye diseases, including macular degeneration, 網膜剥離, uveitis, vitreous hemorrhage, macular hole, epiretinal membrane, and complications related to diabetic retinopathy. These devices enable surgeons to perform delicate procedures within the vitreous and retina, restoring or preserving vision for patients.

The increasing incidence of eye disorders, particularly among the elderly population, is a key driver for the growth of the vitreoretinal surgery devices market. With the aging population, the prevalence of age-related eye diseases such as macular degeneration and diabetic retinopathy is expected to rise, creating a greater demand for effective treatment options.

さらに, the rising geriatric population is expected to contribute to the burden of eye diseases, further driving the market growth. As the elderly population continues to grow, there is a greater need for advanced vitreoretinal surgery devices to address the specific challenges and complexities associated with age-related eye conditions.

In response to the growing demand, companies operating in the vitreoretinal surgery devices market are actively launching new products and forming collaborations to expand their market presence. These initiatives aim to enhance the surgical outcomes, improve patient experience, and address the evolving needs of ophthalmic surgeons.

市場セグメンテーション

市場はさまざまな要因に基づいて分割されます, including product type, surgery type, そして地理.

Segmentation by Product Type
Perfluoro Carbon Liquids
Endoillumination Instruments
Vitreoretinal Prefilled Silicone Oil Syringes
Virectomy System
その他

Segmentation by Surgery Type
Anterior Vitreoretinal Surgery
Posterior Vitreoretinal Surgery

地理によるセグメンテーション
北米 – アメリカ, カナダ, メキシコ
ヨーロッパ – イギリス, ドイツ, フランス, イタリア, スペイン, およびその他のヨーロッパ
アジア太平洋地域 – 中国, 日本, インド, オーストラリア, 韓国, およびその他のアジア太平洋地域
ラテンアメリカ – ブラジル, アルゼンチン, およびその他のラテンアメリカ諸国
中東とアフリカ – GCC, 南アフリカ, およびその他の中東およびアフリカ

Pars plana vitrectomy (PPV) is a widely used technique in vitreoretinal surgery, providing access to the posterior segment of the eye for treating conditions like retinal detachments, vitreous hemorrhage, endophthalmitis, and macular holes. This closed, controlled procedure ensures precise and effective treatment. The demand for posterior vitrectomy, which addresses diseases of the retina and vitreous, is driven by the high prevalence of conditions like diabetic retinopathy and posterior vitreous detachment. その結果, the growth of the posterior vitreoretinal surgery segment is expected to be influenced significantly by these factors, resulting in a substantial market share throughout the forecast period.

North America is expected to have a significant share in the vitreoretinal surgery devices market, driven by the region’s high prevalence of eye diseases and increasing geriatric population. The rising elderly population contributes to market growth, as vitreoretinal surgeries are commonly recommended for age-related eye disorders. Companies in this market are actively launching products and forming partnerships to expand their presence. The high prevalence of eye diseases, along with the growing geriatric population, drives market growth. The posterior vitreoretinal surgery segment holds a substantial market share, and North America is a prominent region in terms of market size. Ongoing advancements and collaborations further contribute to market expansion.

競争環境

The Vitreoretinal Surgery Devices Market is moderately competitive, with global and regional companies. The competitive landscape involves analyzing companies based on factors like product launches, 買収, コラボレーション, and agreements. Notable companies include Alcon AG, バウシュ & ロム・インコーポレーテッド, D.O.R.C. Dutch Ophthalmic Research Center (国際的) B.V., Geuder AG, MedOne Surgical, 株式会社, OCULUS Optikgerate GmbH, とりわけ.

最近の業界の発展

Moria, a French company, successfully acquired AlchimiaSRL, an Italian company, in July 2022. AlchimiaSRL specializes in manufacturing devices for ophthalmic surgery and human tissue banking. This strategic acquisition will enhance Moria’s existing range of products for vitreoretinal surgery and keratoplasty.

In May 2022, D.O.R.C. Dutch Ophthalmic Research Center (国際的) obtained 510(k) premarket approval from the United States Food and Drug Administration (FDA) for their EVA NEXUS Ophthalmic Surgical System. This advanced system is designed for precise subretinal microinjection of gases or aqueous fluids in vitreoretinal ophthalmic surgery.

このレポートを選択する理由

Gain a reliable outlook of the global vitreoretinal surgery devices market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.